About Fredun Pharmaceuticals Ltd
Data last updated: 14 July 2026
Fredun Pharmaceuticals Ltd is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 08 June 1987, the company has been in operation for over 39 years.
Registered with ROC Mumbai under CIN U24239MH1987PLC043662. Listed on BSE: 539730.
Capital: an authorised share capital of ₹50 Cr and a paid-up capital of ₹5.51 Cr. Formerly known as Fredun Pharmaceuticals Private Limited. It is led by directors including Daulat Nariman Medhora and Fredun Nariman Medhora.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.
As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹633.33 Cr, a growth of 40.21% compared to the previous year. The net worth stands at ₹278.11 Cr (up 96.71% YoY). Total assets are valued at ₹642.08 Cr (up 31.73% YoY).
The company has a workforce of approximately 388 employees as per the latest available data.
The company is associated with 1 brand - Fredun Group. As per MCA filings, the company has open charges of ₹293.76 Cr and satisfied charges of ₹172.61 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fredungroup.com.
-
EmailLocked
-
TelephoneLocked
-
WebsiteLocked
-
Social MediaLocked
-
Registered Address11Th Floor Tower A Urmi Estate, 95 Ganpatrao Kadam Marg Lower Parel (W), Mumbai, Maharashtra, India – 400013
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has one previous CIN (Corporate Identification Number): U24239MH1987PLC043662. The current CIN is L24239MH1987PLC043662, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239MH1987PLC043662 | Current |
| U24239MH1987PLC043662 | Previous |
Associated Brands with Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd operates one associated brand: Fredun Group. These brands represent Fredun Pharmaceuticals Ltd's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of pharmaceutical formulations, APIs, and nutraceuticals | fredungroup.com |
Business Activity of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Fredun Pharmaceuticals Ltd
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is audited by R.H.Nisar & Co. (ICAI peer reviewed, certificate valid till 2026-09-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| R.H.Nisar & Co. (ICAI peer reviewed, certificate valid till 2026-09-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is currently managed by 6 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Daulat Nariman Medhora
Also directs:
Fredun Healthcare Private Limited, Fredun Retail Private Limited, Wagr Retail Private Limited and 2 more
|
Whole-Time Director | 08 Jun 1987 | 39 Years 2 Months | Current |
|
Fredun Nariman Medhora
Also directs:
Fredun Healthcare Private Limited, Fredun Retail Private Limited, Wagr Retail Private Limited and 5 more
|
Managing Director | 15 Sep 2006 | 19 Years 11 Months | Current |
| Pooja Narendra Sanghavi | Additional Director | 28 Nov 2025 | 0 Years 8 Months | Current |
| Anshu Gyan Agarwal | Director | 30 Jul 2025 | 1 Years 0 Months | Current |
| Sonal Dharmin Desai | Director | 30 Jul 2025 | 1 Years 0 Months | Current |
|
Daisy Cyril Dsouza
Also directs:
Sanjana Cryogenic Storages Limited
|
Director | 24 Nov 2023 | 2 Years 8 Months | Current |
Financials of Fredun Pharmaceuticals Ltd FY 2026 filings available
Fredun Pharmaceuticals Ltd reported revenue of ₹633.33 Cr (up 40.21% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹633.33 Cr | ₹451.71 Cr |
| Other Income | ₹5.8 Cr | ₹4.56 Cr |
| Total Income | ₹639.12 Cr | ₹456.27 Cr |
| Cost of Materials Consumed | ₹480.76 Cr | ₹323.98 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 |
| Changes in Inventories | -₹31.69 Cr | ₹6.05 Cr |
| Employee Benefit Expense | ₹32.94 Cr | ₹22.23 Cr |
| Finance Costs | ₹39.3 Cr | ₹22.38 Cr |
| Depreciation & Amortisation | ₹8.25 Cr | ₹5.04 Cr |
| Other Expenses | ₹62.57 Cr | ₹49.1 Cr |
| Total Expenses | ₹592.13 Cr | ₹428.78 Cr |
| Profit Before Exceptional Items & Tax | ₹47 Cr | ₹27.49 Cr |
| Exceptional Items | ₹0 | ₹0 |
| Profit Before Tax | ₹47 Cr | ₹27.49 Cr |
| Total Tax Expense | ₹14.38 Cr | ₹7.75 Cr |
| Net Profit | ₹32.62 Cr | ₹19.74 Cr |
| attributable to Owners | - | ₹0 |
| attributable to NCI | - | ₹19,000 |
| Other Comprehensive Income | ₹16.95 Lakh | -₹34.35 Lakh |
| Total Comprehensive Income | ₹32.79 Cr | ₹19.4 Cr |
| EBITDA (computed) | ₹94.54 Cr | ₹54.91 Cr |
| Basic EPS | ₹66.81 | ₹44.83 |
| Diluted EPS | ₹61.23 | ₹44.83 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹642.08 Cr | ₹487.41 Cr |
| Non-current Assets | ₹143.91 Cr | ₹59.46 Cr |
| Current Assets | ₹498.17 Cr | ₹427.95 Cr |
| Property, Plant & Equipment | ₹117.63 Cr | ₹52.49 Cr |
| Inventories | ₹269.8 Cr | ₹239.89 Cr |
| Trade Receivables | ₹92.69 Cr | ₹177.12 Cr |
| Cash & Equivalents | ₹64.93 Cr | ₹63.69 Lakh |
| Equity (Net Worth) | ₹278.11 Cr | ₹141.38 Cr |
| Equity Share Capital | ₹5.47 Cr | ₹4.72 Cr |
| Borrowings (Non-current) | ₹56.31 Cr | ₹16.53 Cr |
| Borrowings (Current) | ₹166.09 Cr | ₹150.61 Cr |
| Total Debt (computed) | ₹222.4 Cr | ₹167.15 Cr |
| Current Liabilities | ₹296.86 Cr | ₹321.18 Cr |
| Total Liabilities | ₹363.97 Cr | ₹346.03 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹26.28 Cr | -₹29.06 Cr |
| Investing Cash Flow | -₹73.59 Cr | -₹6.35 Cr |
| Financing Cash Flow | ₹121.45 Cr | ₹39.12 Cr |
| Capital Expenditure | ₹73.59 Cr | ₹6.11 Cr |
| Free Cash Flow (computed) | -₹47.31 Cr | -₹35.17 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | ₹74.13 Cr | ₹3.7 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹210.41 Cr | ₹159.93 Cr | ₹143.59 Cr | ₹119.4 Cr | ₹165.44 Cr |
| Other Income | ₹2.64 Cr | ₹99.7 Lakh | ₹1.71 Cr | ₹45.21 Lakh | ₹1.97 Cr |
| Total Income | ₹213.06 Cr | ₹160.92 Cr | ₹145.29 Cr | ₹119.86 Cr | ₹167.41 Cr |
| Cost of Materials Consumed | ₹173.54 Cr | ₹118.91 Cr | ₹100.44 Cr | ₹91.08 Cr | ₹125.01 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹22.09 Cr | -₹7.35 Cr | ₹4.41 Cr | -₹6.66 Cr | -₹1.23 Cr |
| Employee Benefit Expense | ₹8.86 Cr | ₹8.15 Cr | ₹8.3 Cr | ₹7.63 Cr | ₹9.7 Cr |
| Finance Costs | ₹14.49 Cr | ₹10.55 Cr | ₹7.73 Cr | ₹6.53 Cr | ₹8.15 Cr |
| Depreciation & Amortisation | ₹3.15 Cr | ₹1.78 Cr | ₹1.89 Cr | ₹1.42 Cr | ₹1.84 Cr |
| Other Expenses | ₹23.86 Cr | ₹14.88 Cr | ₹9.81 Cr | ₹10.81 Cr | ₹16.68 Cr |
| Total Expenses | ₹201.81 Cr | ₹146.92 Cr | ₹132.59 Cr | ₹110.81 Cr | ₹160.14 Cr |
| Profit Before Exceptional Items & Tax | ₹11.25 Cr | ₹14 Cr | ₹12.71 Cr | ₹9.04 Cr | ₹7.26 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹11.25 Cr | ₹14 Cr | ₹12.71 Cr | ₹9.04 Cr | ₹7.26 Cr |
| Total Tax Expense | ₹46.81 Lakh | ₹3.52 Cr | ₹3.27 Cr | ₹2.27 Cr | ₹1.26 Cr |
| Net Profit | ₹10.78 Cr | ₹10.48 Cr | ₹9.43 Cr | ₹6.77 Cr | ₹6 Cr |
| attributable to Owners | - | ₹0 | ₹0 | ₹0 | ₹0 |
| attributable to NCI | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹16.55 Lakh | ₹0 | ₹0 | ₹0 | -₹34.35 Lakh |
| Total Comprehensive Income | ₹10.95 Cr | ₹10.48 Cr | ₹9.43 Cr | ₹6.77 Cr | ₹5.66 Cr |
| EBITDA (computed) | ₹28.88 Cr | ₹26.34 Cr | ₹22.33 Cr | ₹16.99 Cr | ₹17.25 Cr |
| Basic EPS | ₹19.70 | ₹19.53 | ₹19.98 | ₹14.33 | ₹12.71 |
| Diluted EPS | ₹18.22 | ₹17.71 | ₹19.98 | ₹14.33 | ₹12.71 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹633.33 Cr | ₹451.71 Cr | ₹346.58 Cr | ₹274.34 Cr | ₹221.74 Cr | ₹131.55 Cr | ₹110.3 Cr | ₹95.41 Cr |
| Other Income | ₹5.8 Cr | ₹4.56 Cr | ₹2.49 Cr | ₹2.16 Cr | ₹4.35 Cr | ₹3.74 Cr | ₹2.99 Cr | ₹2 Cr |
| Total Income | ₹639.12 Cr | ₹456.27 Cr | ₹349.07 Cr | ₹276.5 Cr | ₹226.09 Cr | ₹135.29 Cr | ₹113.29 Cr | ₹97.4 Cr |
| Cost of Materials Consumed | ₹480.76 Cr | ₹323.98 Cr | ₹282.42 Cr | ₹245.57 Cr | ₹176.45 Cr | ₹100.6 Cr | ₹85.18 Cr | ₹65.96 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹31.69 Cr | ₹6.05 Cr | -₹22.44 Cr | -₹37.72 Cr | -₹58,000 | ₹1.17 Cr | -₹5.04 Cr | -₹6.08 Cr |
| Employee Benefit Expense | ₹32.94 Cr | ₹22.23 Cr | ₹12.5 Cr | ₹11.53 Cr | ₹10.66 Cr | ₹8.66 Cr | ₹8.95 Cr | ₹8.04 Cr |
| Finance Costs | ₹39.3 Cr | ₹22.38 Cr | ₹13.65 Cr | ₹9.28 Cr | ₹4.67 Cr | ₹4.16 Cr | ₹4.41 Cr | ₹3.1 Cr |
| Depreciation & Amortisation | ₹7.91 Cr | ₹4.45 Cr | ₹3.8 Cr | ₹2.81 Cr | ₹2.16 Cr | ₹2 Cr | ₹1.88 Cr | ₹1.33 Cr |
| Other Expenses | ₹62.32 Cr | ₹48.91 Cr | ₹37.69 Cr | ₹27.52 Cr | ₹23.56 Cr | ₹14.33 Cr | ₹9.45 Cr | ₹18.9 Cr |
| Total Expenses | ₹591.54 Cr | ₹428 Cr | ₹327.62 Cr | ₹258.99 Cr | ₹217.49 Cr | ₹130.92 Cr | ₹104.83 Cr | ₹91.24 Cr |
| Profit Before Exceptional Items & Tax | ₹47.58 Cr | ₹28.27 Cr | ₹21.45 Cr | ₹17.51 Cr | ₹8.6 Cr | ₹4.37 Cr | ₹8.46 Cr | ₹6.16 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1.16 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹47.58 Cr | ₹28.27 Cr | ₹21.45 Cr | ₹17.51 Cr | ₹8.6 Cr | ₹3.21 Cr | ₹8.46 Cr | ₹6.16 Cr |
| Total Tax Expense | ₹14.38 Cr | ₹7.46 Cr | ₹5.83 Cr | ₹6.7 Cr | ₹2.26 Cr | ₹1.19 Cr | ₹59.27 Lakh | ₹1.7 Cr |
| Net Profit | ₹33.21 Cr | ₹20.81 Cr | ₹15.62 Cr | ₹10.81 Cr | ₹6.34 Cr | ₹2.01 Cr | ₹7.86 Cr | ₹4.46 Cr |
| Other Comprehensive Income | ₹16.55 Lakh | -₹34.35 Lakh | ₹7.04 Lakh | -₹4.92 Lakh | -₹2.25 Lakh | -₹23,000 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹33.37 Cr | ₹20.46 Cr | ₹15.69 Cr | ₹10.76 Cr | ₹6.31 Cr | ₹2.01 Cr | ₹7.86 Cr | ₹4.46 Cr |
| EBITDA (computed) | ₹94.79 Cr | ₹55.1 Cr | ₹38.9 Cr | ₹29.6 Cr | ₹15.43 Cr | ₹10.54 Cr | ₹14.75 Cr | ₹10.59 Cr |
| Basic EPS | ₹68.01 | ₹44.83 | ₹33.66 | ₹22.93 | ₹14.29 | ₹5.05 | ₹4.77 | ₹11.17 |
| Diluted EPS | ₹62.33 | ₹44.83 | ₹33.32 | ₹22.93 | ₹14.29 | ₹5.05 | ₹4.77 | ₹11.17 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹642.14 Cr | ₹486.65 Cr | ₹307.6 Cr | ₹257.28 Cr | ₹186.99 Cr | ₹161.62 Cr | ₹133.16 Cr | ₹104.91 Lakh Cr |
| Non-current Assets | ₹143.89 Cr | ₹59.12 Cr | ₹50.4 Cr | ₹41.07 Cr | ₹34.34 Cr | ₹31.54 Cr | ₹32.05 Cr | ₹32.39 Lakh Cr |
| Current Assets | ₹498.24 Cr | ₹427.53 Cr | ₹257.2 Cr | ₹216.21 Cr | ₹152.65 Cr | ₹130.08 Cr | ₹101.11 Cr | ₹72.52 Lakh Cr |
| Property, Plant & Equipment | ₹117.61 Cr | ₹52.14 Cr | ₹46.15 Cr | ₹38.63 Cr | ₹32.28 Cr | ₹30.32 Cr | ₹30.93 Cr | ₹31.35 Lakh Cr |
| Inventories | ₹269.8 Cr | ₹239.89 Cr | ₹175 Cr | ₹150.12 Cr | ₹46.46 Cr | ₹67.57 Cr | ₹50.46 Cr | ₹40.78 Lakh Cr |
| Trade Receivables | ₹92.69 Cr | ₹177.12 Cr | ₹64.85 Cr | ₹34.56 Cr | ₹90.27 Cr | ₹41.08 Cr | ₹32.79 Cr | ₹17.78 Lakh Cr |
| Cash & Equivalents | ₹64.9 Cr | ₹22.96 Lakh | ₹1.07 Cr | ₹2.95 Cr | ₹1.94 Cr | ₹99.46 Lakh | ₹2.75 Cr | ₹80,927 Cr |
| Equity (Net Worth) | ₹278.71 Cr | ₹141.4 Cr | ₹121.47 Cr | ₹96.38 Cr | ₹68.06 Cr | ₹43.07 Cr | ₹41.32 Cr | ₹38.99 Lakh Cr |
| Equity Share Capital | ₹5.47 Cr | ₹4.72 Cr | ₹4.7 Cr | ₹4.53 Cr | ₹4.43 Cr | ₹3.99 Cr | ₹3.99 Cr | ₹398,963 Cr |
| Borrowings (Non-current) | ₹56.31 Cr | ₹9.61 Cr | ₹5.15 Cr | ₹48.93 Cr | ₹42.04 Cr | ₹29.11 Cr | ₹11.5 Cr | ₹0 |
| Borrowings (Current) | ₹165.72 Cr | ₹156.79 Cr | ₹100.36 Cr | ₹37.6 Cr | ₹10.73 Cr | ₹10.53 Cr | ₹23.41 Cr | ₹0 |
| Total Debt (computed) | ₹222.03 Cr | ₹166.41 Cr | ₹105.51 Cr | ₹86.52 Cr | ₹52.76 Cr | ₹39.64 Cr | ₹34.9 Cr | ₹0 |
| Current Liabilities | ₹296.31 Cr | ₹327.32 Cr | ₹174.47 Cr | ₹106.17 Cr | ₹73.75 Cr | ₹86.46 Cr | ₹77.78 Cr | ₹38.18 Lakh Cr |
| Total Liabilities | ₹363.43 Cr | ₹345.25 Cr | ₹186.13 Cr | ₹160.9 Cr | ₹118.93 Cr | ₹118.55 Cr | ₹91.84 Cr | ₹65.92 Lakh Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹30.81 Cr | -₹28.88 Cr | -₹43.87 Lakh | -₹14.41 Cr | -₹2.38 Cr |
| Investing Cash Flow | -₹73.58 Cr | -₹5.99 Cr | -₹7.64 Cr | -₹9.4 Cr | -₹4.14 Cr |
| Financing Cash Flow | ₹121.82 Cr | ₹38.34 Cr | ₹5.99 Cr | ₹25.18 Cr | ₹7.47 Cr |
| Capital Expenditure | ₹73.58 Cr | ₹5.99 Cr | ₹7.64 Cr | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹42.77 Cr | -₹34.88 Cr | -₹8.08 Cr | -₹14.41 Cr | -₹2.38 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹79.05 Cr | ₹3.47 Cr | -₹2.08 Cr | ₹1.36 Cr | ₹94.36 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹210.41 Cr | ₹159.93 Cr | ₹143.59 Cr | ₹119.4 Cr | ₹165.44 Cr | ₹101.84 Cr | ₹106.89 Cr | ₹77.54 Cr |
| Other Income | ₹2.64 Cr | ₹99.7 Lakh | ₹1.71 Cr | ₹45.21 Lakh | ₹1.97 Cr | ₹85.58 Lakh | ₹46.16 Lakh | ₹1.28 Cr |
| Total Income | ₹213.05 Cr | ₹160.92 Cr | ₹145.29 Cr | ₹119.86 Cr | ₹167.41 Cr | ₹102.7 Cr | ₹107.35 Cr | ₹78.81 Cr |
| Cost of Materials Consumed | ₹173.54 Cr | ₹118.91 Cr | ₹99.26 Cr | ₹91.08 Cr | ₹125.01 Cr | ₹72.66 Cr | ₹67.4 Cr | ₹57.88 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹22.09 Cr | -₹7.35 Cr | ₹4.41 Cr | -₹6.66 Cr | -₹1.23 Cr | -₹26.07 Lakh | ₹7.87 Cr | -₹32.68 Lakh |
| Employee Benefit Expense | ₹8.86 Cr | ₹8.15 Cr | ₹8.3 Cr | ₹7.63 Cr | ₹9.7 Cr | ₹5.85 Cr | ₹3.58 Cr | ₹3.1 Cr |
| Finance Costs | ₹14.49 Cr | ₹10.55 Cr | ₹7.73 Cr | ₹6.53 Cr | ₹8.15 Cr | ₹5 Cr | ₹5.31 Cr | ₹3.91 Cr |
| Depreciation & Amortisation | ₹3.11 Cr | ₹1.78 Cr | ₹1.6 Cr | ₹1.42 Cr | ₹1.25 Cr | ₹1.09 Cr | ₹1.06 Cr | ₹1.05 Cr |
| Other Expenses | ₹23.61 Cr | ₹14.88 Cr | ₹10.99 Cr | ₹10.81 Cr | ₹16.49 Cr | ₹11.22 Cr | ₹14.55 Cr | ₹7.68 Cr |
| Total Expenses | ₹201.52 Cr | ₹146.92 Cr | ₹132.29 Cr | ₹110.81 Cr | ₹159.37 Cr | ₹95.56 Cr | ₹99.78 Cr | ₹73.29 Cr |
| Profit Before Exceptional Items & Tax | ₹11.53 Cr | ₹14 Cr | ₹13.01 Cr | ₹9.04 Cr | ₹8.04 Cr | ₹7.13 Cr | ₹7.58 Cr | ₹5.52 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹11.53 Cr | ₹14 Cr | ₹13.01 Cr | ₹9.04 Cr | ₹8.04 Cr | ₹7.13 Cr | ₹7.58 Cr | ₹5.52 Cr |
| Total Tax Expense | ₹46.81 Lakh | ₹3.52 Cr | ₹3.27 Cr | ₹2.27 Cr | ₹96.99 Lakh | ₹1.8 Cr | ₹3.3 Cr | ₹1.39 Cr |
| Net Profit | ₹11.07 Cr | ₹10.48 Cr | ₹9.73 Cr | ₹6.77 Cr | ₹7.07 Cr | ₹5.33 Cr | ₹4.27 Cr | ₹4.13 Cr |
| Other Comprehensive Income | ₹16.55 Lakh | ₹0 | ₹0 | ₹0 | -₹34.35 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹11.23 Cr | ₹10.48 Cr | ₹9.73 Cr | ₹6.77 Cr | ₹6.73 Cr | ₹5.33 Cr | ₹4.27 Cr | ₹4.13 Cr |
| EBITDA (computed) | ₹29.13 Cr | ₹26.34 Cr | ₹22.34 Cr | ₹16.99 Cr | ₹17.44 Cr | ₹13.23 Cr | ₹13.95 Cr | ₹10.48 Cr |
| Basic EPS | ₹20.22 | ₹19.53 | ₹20.61 | ₹14.33 | ₹14.98 | ₹11.29 | ₹9.05 | ₹8.79 |
| Diluted EPS | ₹18.70 | ₹17.71 | ₹20.61 | ₹14.33 | ₹14.98 | ₹11.29 | ₹9.05 | ₹8.79 |
Charges & Borrowings of Fredun Pharmaceuticals Ltd
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 May 2026 | Others | ₹2 Cr | Open |
| 30 Apr 2026 | Others | ₹1.06 Cr | Open |
| 15 Apr 2026 | Others | ₹35 Cr | Open |
| 26 Feb 2026 | Others | ₹20 Cr | Open |
| 22 Feb 2026 | Others | ₹3.78 Cr | Open |
Total charge records: 83 View all charges
Employees and EPFO Compliance at Fredun Pharmaceuticals Ltd
View historical data on people associated with Fredun Pharmaceuticals Ltd, including employment history and EPFO contributions.
Employee and EPFO history for Fredun Pharmaceuticals Ltd
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Fredun Pharmaceuticals Ltd
GST registrations and filing compliance for Fredun Pharmaceuticals Ltd
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Fredun Pharmaceuticals Ltd
Credit ratings, litigation, and regulatory alerts for Fredun Pharmaceuticals Ltd
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Fredun Pharmaceuticals Ltd
MSME payment history for Fredun Pharmaceuticals Ltd
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Fredun Pharmaceuticals Ltd
Corporate group structure for Fredun Pharmaceuticals Ltd
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Fredun Pharmaceuticals Ltd
MCA filings and documents for Fredun Pharmaceuticals Ltd
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Fredun Pharmaceuticals Ltd
Frequently Asked Questions about Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 08 June 1987 (39+ years old) and is registered under CIN L24239MH1987PLC043662. Listed on BSE: 539730. The company has 388 employees.
Fredun Pharmaceuticals Ltd reported revenue of ₹633.33 Cr for FY 2026 (up 40.21% YoY) based on consolidated BSE filings.
The current directors of Fredun Pharmaceuticals Ltd are:
- Daulat Nariman Medhora - Whole-Time Director
- Fredun Nariman Medhora - Managing Director
- Pooja Narendra Sanghavi - Additional Director
- Anshu Gyan Agarwal - Director
- Sonal Dharmin Desai - Director
- Daisy Cyril Dsouza - Director
The primary industry of Fredun Pharmaceuticals Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Fredun Pharmaceuticals Ltd is listed on BSE with code 539730.
Fredun Pharmaceuticals Ltd can be reached at the registered office: 11Th Floor Tower A Urmi Estate, 95 Ganpatrao Kadam Marg Lower Parel W, Mumbai, Maharashtra, India – 400013, or through the website fredungroup.com.